Skin Disorders News

New results evaluating the efficacy and safety of nemolizumab for the treatment of adult and adolescent patients with moderate to severe atopic dermatitis were published in The Lancet, Galderma announced in a press release.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of Anzupgo for the treatment of chronic hand eczema in adults, LEO Pharma announced in a press release.

Responses to baricitinib and dupilumab were notable and similar among patients with moderate to severe atopic dermatitis in a real-world setting, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

The risk of developing alopecia areata increases when both seasonal and food allergies are present, according to a study published in The European Journal of Allergy and Clinical Immunology.

While the art of tattooing has been present for centuries, the medical implications are only recently coming to light with modern medicine.

KalVista Pharmaceuticals Inc. submitted a new drug application to the FDA for the approval of sebetralstat for patients aged 12 years and older with hereditary angioedema, according to a company press release.

Instead of patch testing with all allergens in any given group, using an optimized subset of allergens to test for allergic contact dermatitis can provide a similar level of care at a reduced cost, according to a study.

Seborrheic dermatitis is more prevalent across the world than previously believed, with a global pooled prevalence of 4.38%, according to a comprehensive meta-analysis.

Enrollment has been completed in a phase 2 clinical trial for the evaluation of bempikibart as a treatment for adults with persistent, moderate to severe atopic dermatitis, Q32 Bio announced in a press release.

The FDA has approved Zoryve cream 0.15% for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged 6 years and older, Arcutis announced in a press release.